$BCTX
BriaCell Therapeutics Corp.

2024 Q4 Form 10-Q Financial Statement

#000149315224050214 Filed on December 16, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2023 Q4
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.646M
YoY Change -23.38%
% of Gross Profit
Research & Development $3.665M $6.857M
YoY Change -46.55% 110.65%
% of Gross Profit
Depreciation & Amortization $22.84K $3.820K
YoY Change 497.88% 0.05%
% of Gross Profit
Operating Expenses $5.153M $8.503M
YoY Change -39.4% 57.37%
Operating Profit -$5.153M -$8.503M
YoY Change -39.4% 57.37%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $11.71K $14.46M
YoY Change -99.92% 236.59%
Pretax Income $5.959M
YoY Change -638.51%
Income Tax
% Of Pretax Income
Net Earnings -$5.802M $6.002M
YoY Change -196.68% -642.37%
Net Earnings / Revenue
Basic Earnings Per Share -$0.22 $0.38
Diluted Earnings Per Share -$0.22 -$0.50
COMMON SHARES
Basic Shares Outstanding 36.18M shares 15.98M shares
Diluted Shares Outstanding 26.64M shares 16.67M shares

Balance Sheet

Concept 2024 Q4 2023 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $13.65M
YoY Change -63.56%
Cash & Equivalents $5.792M $13.65M
Short-Term Investments
Other Short-Term Assets $4.741M
YoY Change 538.81%
Inventory
Prepaid Expenses $4.741M
Receivables $21.41K
Other Receivables $0.00
Total Short-Term Assets $8.219M $18.41M
YoY Change -55.35% -51.84%
LONG-TERM ASSETS
Property, Plant & Equipment $365.3K
YoY Change
Goodwill
YoY Change
Intangibles $196.0K
YoY Change
Long-Term Investments $2.00
YoY Change 0.0%
Other Assets
YoY Change
Total Long-Term Assets $2.195M $211.3K
YoY Change 939.15% -6.74%
TOTAL ASSETS
Total Short-Term Assets $8.219M $18.41M
Total Long-Term Assets $2.195M $211.3K
Total Assets $10.41M $18.62M
YoY Change -44.07% -51.58%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.047M
YoY Change 32.18%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $4.989M $1.047M
YoY Change 376.69% 7.44%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $15.06M
YoY Change -44.53%
Total Long-Term Liabilities $1.713M $15.06M
YoY Change -88.62% -44.53%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.989M $1.047M
Total Long-Term Liabilities $1.713M $15.06M
Total Liabilities $6.701M $16.10M
YoY Change -58.38% -42.73%
SHAREHOLDERS EQUITY
Retained Earnings -$91.25M -$74.65M
YoY Change 22.23% 21.47%
Common Stock $82.04M $69.59M
YoY Change 17.89% -3.25%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $2.721M
YoY Change
Total Liabilities & Shareholders Equity $10.41M $18.62M
YoY Change -44.07% -51.58%

Cashflow Statement

Concept 2024 Q4 2023 Q4
OPERATING ACTIVITIES
Net Income -$5.802M $6.002M
YoY Change -196.68% -642.37%
Depreciation, Depletion And Amortization $22.84K $3.820K
YoY Change 497.88% 0.05%
Cash From Operating Activities -$6.955M -$7.605M
YoY Change -8.55% 114.69%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$75.00K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $11.96M
YoY Change
NET CHANGE
Cash From Operating Activities -$6.955M -$7.605M
Cash From Investing Activities -$75.00K
Cash From Financing Activities $11.96M
Net Change In Cash $4.930M -$7.605M
YoY Change -164.83% 111.86%
FREE CASH FLOW
Cash From Operating Activities -$6.955M -$7.605M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q4 us-gaap Common Stock Shares Authorized Unlimited
CommonStockSharesAuthorizedUnlimited
Unlimited
CY2024Q4 dei Amendment Flag
AmendmentFlag
false
CY2024Q4 dei Entity File Number
EntityFileNumber
001-40101
CY2024Q4 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2024Q4 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--07-31
CY2024Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2024Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3665341 usd
CY2024Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1487491 usd
CY2023Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1645771 usd
CY2023Q4 us-gaap Operating Expenses
OperatingExpenses
8503028 usd
CY2024Q4 dei Entity Registrant Name
EntityRegistrantName
BRIACELL THERAPEUTICS CORP.
CY2024Q4 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-1099599
CY2024Q4 dei Entity Address Address Line1
EntityAddressAddressLine1
235 15th Street, Suite 300
CY2024Q4 dei Entity Address City Or Town
EntityAddressCityOrTown
West Vancouver
CY2024Q4 dei Entity Address State Or Province
EntityAddressStateOrProvince
BC
CY2024Q4 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
V7T 2X1
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
862089 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
21251092 usd
CY2024Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5792265 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
13645847 usd
CY2023Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15981726 shares
CY2024Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.22
CY2024Q4 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2025
CY2024Q4 dei Entity Central Index Key
EntityCentralIndexKey
0001610820
CY2024 us-gaap Common Stock Shares Authorized Unlimited
CommonStockSharesAuthorizedUnlimited
Unlimited
CY2023Q4 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
usd
CY2024Q4 BCTX Stock Issued During Period Value Exercise Of Prefunded Warrants
StockIssuedDuringPeriodValueExerciseOfPrefundedWarrants
usd
CY2023Q4 us-gaap Depreciation
Depreciation
usd
CY2023Q4 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
usd
CY2023Q4 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
usd
CY2023Q4 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
usd
CY2023Q4 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
usd
CY2023Q4 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
usd
CY2023Q4 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
usd
CY2024Q4 us-gaap Common Stock Shares Authorized Unlimited
CommonStockSharesAuthorizedUnlimited
Unlimited
CY2024 us-gaap Common Stock Shares Authorized Unlimited
CommonStockSharesAuthorizedUnlimited
Unlimited
CY2024Q4 BCTX Change In Fair Value Of Warrant Liability
ChangeInFairValueOfWarrantLiability
usd
CY2024Q4 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
shares
CY2024Q4 BCTX Incremental Common Shares Attributable To Warrants
IncrementalCommonSharesAttributableToWarrants
shares
CY2024Q4 dei Document Type
DocumentType
10-Q
CY2024Q4 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2024Q4 dei Document Period End Date
DocumentPeriodEndDate
2024-10-31
CY2024Q4 dei Document Transition Report
DocumentTransitionReport
false
CY2024Q4 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
A1
CY2024Q4 dei City Area Code
CityAreaCode
604
CY2024Q4 dei Local Phone Number
LocalPhoneNumber
921-1810
CY2024Q4 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024Q4 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q4 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2024Q4 dei Entity Small Business
EntitySmallBusiness
true
CY2024Q4 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2024Q4 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2024Q4 dei Entity Shell Company
EntityShellCompany
true
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
44204161 shares
CY2024Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5792265 usd
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
862089 usd
CY2024Q4 BCTX Accounts Receivable And Prepaid Expenses Current
AccountsReceivableAndPrepaidExpensesCurrent
2426830 usd
CY2024Q3 BCTX Accounts Receivable And Prepaid Expenses Current
AccountsReceivableAndPrepaidExpensesCurrent
2791765 usd
CY2024Q4 us-gaap Assets Current
AssetsCurrent
8219095 usd
CY2024Q3 us-gaap Assets Current
AssetsCurrent
3653854 usd
CY2024Q4 us-gaap Equity Securities Fvni Noncurrent
EquitySecuritiesFVNINoncurrent
421975 usd
CY2024Q3 us-gaap Equity Securities Fvni Noncurrent
EquitySecuritiesFVNINoncurrent
418490 usd
CY2024Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
195978 usd
CY2024Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
199796 usd
CY2024Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
365336 usd
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
388175 usd
CY2024Q4 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
1211946 usd
CY2024Q3 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
1211946 usd
CY2024Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
2195235 usd
CY2024Q3 us-gaap Assets Noncurrent
AssetsNoncurrent
2218407 usd
CY2024Q4 us-gaap Assets
Assets
10414330 usd
CY2024Q3 us-gaap Assets
Assets
5872261 usd
CY2024Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
4233968 usd
CY2024Q3 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
7170781 usd
CY2024Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
754668 usd
CY2024Q3 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
290376 usd
CY2024Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4988636 usd
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
7461157 usd
CY2024Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
1712679 usd
CY2024Q3 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
1096036 usd
CY2024Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
1712679 usd
CY2024Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
1096036 usd
CY2024Q3 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2024Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
36183161 shares
CY2024Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
36183161 shares
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
18284661 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
18284661 shares
CY2024Q4 us-gaap Common Stock Value
CommonStockValue
82040741 usd
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
72166414 usd
CY2024Q4 BCTX Sharebased Payment Reserve
SharebasedPaymentReserve
9456232 usd
CY2024Q3 BCTX Sharebased Payment Reserve
SharebasedPaymentReserve
9189261 usd
CY2024Q4 BCTX Warrant Reserve
WarrantReserve
3930221 usd
CY2024Q3 BCTX Warrant Reserve
WarrantReserve
1844296 usd
CY2024Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-138684 usd
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-138684 usd
CY2024Q4 us-gaap Minority Interest
MinorityInterest
-329623 usd
CY2024Q3 us-gaap Minority Interest
MinorityInterest
-302522 usd
CY2024Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-91245872 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-85443697 usd
CY2024Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
3713015 usd
CY2024Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-2684932 usd
CY2024Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
10414330 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5872261 usd
CY2023Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6857257 usd
CY2024Q4 us-gaap Operating Expenses
OperatingExpenses
5152832 usd
CY2024Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-5152832 usd
CY2023Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-8503028 usd
CY2024Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
11714 usd
CY2023Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
179822 usd
CY2024Q4 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
616643 usd
CY2023Q4 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-14282078 usd
CY2024Q4 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-71515 usd
CY2024Q4 us-gaap Profit Loss
ProfitLoss
-5829276 usd
CY2023Q4 us-gaap Profit Loss
ProfitLoss
5958872 usd
CY2024Q4 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-27101 usd
CY2023Q4 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-42671 usd
CY2024Q4 us-gaap Net Income Loss
NetIncomeLoss
-5802175 usd
CY2023Q4 us-gaap Net Income Loss
NetIncomeLoss
6001543 usd
CY2024Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.22
CY2023Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.38
CY2024Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.22
CY2023Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.50
CY2024Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26641036 shares
CY2023Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15981726 shares
CY2024Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
26641036 shares
CY2023Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
16674891 shares
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-3777181 usd
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-3777181 usd
CY2023Q4 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
-199207 usd
CY2023Q4 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
533816 usd
CY2023Q4 us-gaap Profit Loss
ProfitLoss
5958872 usd
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
2516300 usd
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
2516300 usd
CY2024Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-2684932 usd
CY2024Q4 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
266971 usd
CY2024Q4 BCTX Stock Issued During Period Value Exercise Of Broker Warrants
StockIssuedDuringPeriodValueExerciseOfBrokerWarrants
293251 usd
CY2024Q4 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
11667001 usd
CY2024Q4 us-gaap Profit Loss
ProfitLoss
-5829276 usd
CY2024Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
3713015 usd
CY2024Q4 us-gaap Profit Loss
ProfitLoss
-5829276 usd
CY2023Q4 us-gaap Profit Loss
ProfitLoss
5958872 usd
CY2024Q4 us-gaap Adjustment For Amortization
AdjustmentForAmortization
3818 usd
CY2023Q4 us-gaap Adjustment For Amortization
AdjustmentForAmortization
3818 usd
CY2024Q4 us-gaap Depreciation
Depreciation
22839 usd
CY2024Q4 us-gaap Share Based Compensation
ShareBasedCompensation
266971 usd
CY2023Q4 us-gaap Share Based Compensation
ShareBasedCompensation
533816 usd
CY2024Q4 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-71515 usd
CY2024Q4 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
616643 usd
CY2023Q4 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-14282078 usd
CY2024Q4 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-736788 usd
CY2023Q4 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2537 usd
CY2024Q4 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
371853 usd
CY2023Q4 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-937816 usd
CY2024Q4 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2936813 usd
CY2023Q4 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-689824 usd
CY2024Q4 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
464292 usd
CY2023Q4 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-65128 usd
CY2024Q4 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6955076 usd
CY2023Q4 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7605245 usd
CY2024Q4 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
75000 usd
CY2024Q4 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-75000 usd
CY2024Q4 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
293251 usd
CY2024Q4 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
11667001 usd
CY2024Q4 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
11960252 usd
CY2024Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
4930176 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-7605245 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
862089 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
21251092 usd
CY2024Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5792265 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
13645847 usd
CY2024Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-91245872 usd
CY2024Q4 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6955076 usd
CY2024Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
8500000 usd
CY2024Q4 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
5000000.0 usd
CY2024Q4 us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_845_eus-gaap--UseOfEstimates_zgjRwH9z00b8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a. <span id="xdx_868_zFiKYVCTnan8">Use of estimates</span>:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: top; text-align: left"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. The Company’s management believes that the estimates, judgment and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities at the dates of the condensed consolidated financial statements, and the reported amount of expenses during the reporting periods. Actual results could differ from those estimates.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-91245872 usd
CY2024Q4 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6955076 usd
CY2024Q4 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
5000000.0 usd
CY2024Q4 us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_845_eus-gaap--UseOfEstimates_zgjRwH9z00b8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a. <span id="xdx_868_zFiKYVCTnan8">Use of estimates</span>:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: top; text-align: left"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. The Company’s management believes that the estimates, judgment and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities at the dates of the condensed consolidated financial statements, and the reported amount of expenses during the reporting periods. Actual results could differ from those estimates.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
5792265 usd
CY2024Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
862089 usd
CY2024Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
1712679 usd
CY2024Q3 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
1096036 usd
CY2024Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2024Q3 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2024Q4 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
75000 usd
CY2024Q4 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
60000 shares
CY2024Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
5792265 usd
CY2024Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
862089 usd
CY2024Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
1712679 usd
CY2024Q3 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
1096036 usd
CY2024Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2024Q3 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2024Q4 us-gaap Share Price
SharePrice
0.81
CY2024Q3 us-gaap Share Price
SharePrice
0.75
CY2024Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2024 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2024 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0427 pure
CY2024Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
2131400 shares
CY2024Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
2018775 shares
CY2024Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
2131400 shares
CY2024Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
2131400 shares
CY2024Q4 us-gaap Share Price
SharePrice
0.81
CY2024Q3 us-gaap Share Price
SharePrice
0.75
CY2024Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2024 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2024 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0427 pure
CY2024Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
2131400 shares
CY2024Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
2018775 shares
CY2024Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
2131400 shares
CY2024Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
2131400 shares
CY2024Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
2018775 shares
CY2024Q4 us-gaap Share Based Compensation
ShareBasedCompensation
266971 usd
CY2023Q4 us-gaap Share Based Compensation
ShareBasedCompensation
533816 usd
CY2024Q4 us-gaap Net Income Loss
NetIncomeLoss
-5802175 usd
CY2023Q4 us-gaap Net Income Loss
NetIncomeLoss
6001543 usd
CY2024Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26641036 shares
CY2023Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15981726 shares
CY2024Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.22
CY2023Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.38
CY2024Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5802175 usd
CY2023Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
6001543 usd
CY2023Q4 BCTX Change In Fair Value Of Warrant Liability
ChangeInFairValueOfWarrantLiability
-14282078 usd
CY2024Q4 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-5802175 usd
CY2023Q4 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-8280535 usd
CY2024Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26641036 shares
CY2023Q4 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
211434 shares
CY2023Q4 BCTX Incremental Common Shares Attributable To Warrants
IncrementalCommonSharesAttributableToWarrants
481731 shares
CY2024Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
26641036 shares
CY2024Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.22
CY2023Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.50
CY2024Q4 us-gaap Investment Income Interest
InvestmentIncomeInterest
13050 usd
CY2023Q4 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-10993 usd
CY2024Q4 us-gaap Share Based Compensation
ShareBasedCompensation
266971 usd
CY2023Q4 us-gaap Share Based Compensation
ShareBasedCompensation
533816 usd
CY2024Q4 us-gaap Net Income Loss
NetIncomeLoss
-5802175 usd
CY2023Q4 us-gaap Net Income Loss
NetIncomeLoss
6001543 usd
CY2024Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26641036 shares
CY2023Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15981726 shares
CY2024Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.22
CY2023Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.38
CY2024Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5802175 usd
CY2023Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
6001543 usd
CY2023Q4 BCTX Change In Fair Value Of Warrant Liability
ChangeInFairValueOfWarrantLiability
-14282078 usd
CY2023Q4 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-8280535 usd
CY2024Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26641036 shares
CY2023Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15981726 shares
CY2023Q4 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
211434 shares
CY2023Q4 BCTX Incremental Common Shares Attributable To Warrants
IncrementalCommonSharesAttributableToWarrants
481731 shares
CY2024Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
26641036 shares
CY2023Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
16674891 shares
CY2024Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.22
CY2023Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.50
CY2024Q4 us-gaap Investment Income Interest
InvestmentIncomeInterest
13050 usd
CY2023Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.38
CY2024Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5802175 usd
CY2023Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
6001543 usd
CY2024Q4 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-5802175 usd
CY2023Q4 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-8280535 usd
CY2024Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26641036 shares
CY2024Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.22
CY2023Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.50
CY2024Q4 us-gaap Investment Income Interest
InvestmentIncomeInterest
13050 usd
CY2023Q4 us-gaap Investment Income Interest
InvestmentIncomeInterest
190815 usd
CY2024Q4 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-1336 usd
CY2023Q4 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-10993 usd
CY2024Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
11714 usd
CY2023Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
179822 usd
CY2023Q4 us-gaap Investment Income Interest
InvestmentIncomeInterest
190815 usd
CY2023Q4 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-10993 usd
CY2024Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
11714 usd
CY2023Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
179822 usd
CY2024Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
11714 usd
CY2023Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
179822 usd

Files In Submission

Name View Source Status
0001493152-24-050214-index-headers.html Edgar Link pending
0001493152-24-050214-index.html Edgar Link pending
0001493152-24-050214.txt Edgar Link pending
0001493152-24-050214-xbrl.zip Edgar Link pending
bctx-20241031.xsd Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
ex32-2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
bctx-20241031_def.xml Edgar Link unprocessable
bctx-20241031_lab.xml Edgar Link unprocessable
bctx-20241031_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
0001493152-24-050214-index-headers.html Edgar Link pending
0001493152-24-050214-index.html Edgar Link pending
0001493152-24-050214.txt Edgar Link pending
0001493152-24-050214-xbrl.zip Edgar Link pending
bctx-20241031.xsd Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
ex32-2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
bctx-20241031_def.xml Edgar Link unprocessable
bctx-20241031_lab.xml Edgar Link unprocessable
bctx-20241031_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
form10-q_htm.xml Edgar Link completed
bctx-20241031_cal.xml Edgar Link unprocessable
bctx-20241031_cal.xml Edgar Link unprocessable